Mike Blake/REUTERS A new drug showed 100% effectiveness in preventing HIV in women, according to new results from an ongoing clinical trial. The pre-exposure prophylaxis (PrEP) drug, lenacapavir, appeared to be so effective that pharma company Gilead has ended the trial early because it was exceeding expectations, and outperforming existing drugs. Lenacapavir is different from existing PrEP treatments because, unlike daily pills, it can be given in biannual doses. Study participants were sorted into two groups: 2,314 women and girls at risk of HIV got lenacapvir, while another 3,204 received daily PrEP drugs. None of the participants who got lenacapavir contracted HIV, while 55 of the people in the other group did. One researcher described it as a “remarkable result.” |